Mallax Pharmaceuticals
Mallax Pharmaceuticals at a glance
Mallax was established in Q4 2020 by Impilo with an ambition to build a large and well-diversified platform of established pharmaceuticals and OTC products, with a wide size range for any individual deal between EUR 10m and EUR 300m. Mallax’s first acquisition, Sana Pharma Medical AS (“SPM”), was signed and closed in June 2021.
Mallax facts
Sector
Pharmaceuticals
Impilo entry date
December 2020
Impilo exit date
August 2023
HQ
Oslo, Norway
Impilo team
Magnus Edlund
Victor Steien
Edvard Hubendick
Acquirer
Acquired by the original founders
Investment thesis
- Build a well-diversified pan-European platform of established pharmaceuticals and OTC products through active business development
- Underlying markets characterized by stable growth, low cyclicality,and high deal flow
- Five-year ambition to invest c. SEK 1bn of equity in acquisitions, in-licensing and partnership agreements
- Mallax will have a positive health and ESG-impact taking all aspectsof the supply chain into consideration
UN SDG Goals
Other portfolio companies
Avia Pharma
Avia is a leading North European OTC/Rx platform
Read More
Stille
Stille is a well-established pioneer in the development of premium surgical instruments and advanced surgical tables
Read More
Decon
Decon develops, assembles, and distributes high-quality, power-assisted electrical solutions for wheelchairs
Read More